Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase 2 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with acute coronary syndromes (ACS), preclinical data evaluating rNAPc2 in mouse models of colorectal cancer, and preclinical data evaluating the mechanism of NU172, a short-acting, direct thrombin inhibiting aptamer, will be presented at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH) taking place in Geneva, Switzerland, July 6-12, 2007.
The presentation details are as
follows:
Date/Time: Sunday, July 8, 2007, 5:30 p.m.
CEST
Poster Session (P-S-016): Tissue Factor/Factor
VIIa Inhibitor Reduces
Ischemia in Patients with NSTE-ACS: Final
Results of the ANTHEM-TIMI
32 Trial
Date/Time: Sunday, July 8, 2007, 5:30 p.m.
CEST
Poster Session (P-S-067): Discovery of a
Potent, Direct Thrombin
Inhibiting Aptamer
Date/Time: Sunday, July 8, 2007, 5:30 p.m.
CEST
Poster Session (P-S-072):
Pharmacokinetic/Pharmacodynamic Profile of a
Novel Aptamer Direct Thrombin Inhibitor in
Cynomolgus Monkeys and
Yorkshire Pigs Following a Single IV Bolus
Administration
Date/Time: Monday, July 9, 2007, 10:00 a.m.
CEST
Oral Presentation (O-M-001): rNAPc2, a Novel
Inhibitor of Tissue
Factor/Factor VIIa Complex, Synergizes
with 5-FU or Bevacizumab in a
Mouse Model of Colorectal Cancer
Date/Time: Tuesday, July 10, 2007, 5:30 p.m.
CEST
Poster Session (P-T-509): rNAPc2, a Novel
Inhibitor of Tissue
Factor/Factor VIIa Complex, Suppresses
Liver and Lung Metastases in Mouse
Models of Colorectal Cancer
About NuveloNuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.
This press release contains "forward-looking statements," which include statements regarding the timing and progress of Nuvelo's clinical stage and preclinical research programs, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes and uncertainties relating to our ability to obtain funding. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.
SOURCE Nuvelo, Inc.
-0-
07/05/2007
/CONTACT: Nicole Foderaro, Director,
Corporate Communications & IR of
Nuvelo, Inc., +1-650-517-8472, nfoderaro@nuvelo.com; or Carolyn
Bumgardner
Wang of WeissComm Partners, Inc., +1-415-225-5050,
carolyn@weisscommpartners.com,
for Nuvelo, Inc./
/Web site: http://www.nuvelo.com /
(NUVO)
